Status of the development of a vaccine against Mycoplasma bovis

Vaccine. 2017 May 19;35(22):2902-2907. doi: 10.1016/j.vaccine.2017.03.095. Epub 2017 Apr 19.

Abstract

Mycoplasma bovis is an important pathogen of cattle and, despite numerous efforts an effective vaccine for control of the disease it causes remains elusive. Although we now know more about the biology of this pathogen, information is lacking about appropriate protective antigens, the type of immune response that confers protection and adjuvants selection. The use of conserved recombinant proteins, selected using in silico approaches, as components of a vaccine may be a better choice over bacterin-based vaccines due to the limited protection afforded by them and adverse reactions caused by them. More studies are needed on the characterization of host-pathogen interactions and to elucidate M. bovis products modulating these interactions. These products could be the basis for development of vaccines to control M. bovis infections in dairy farms and feedlots.

Keywords: Mycoplasma bovis; New approaches; Vaccines.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Antibodies, Bacterial / biosynthesis
  • Antigens, Bacterial / genetics
  • Antigens, Bacterial / immunology*
  • Bacterial Vaccines / immunology*
  • Cattle
  • Cattle Diseases / immunology
  • Cattle Diseases / prevention & control*
  • Drug Discovery
  • Mycoplasma Infections / immunology
  • Mycoplasma Infections / prevention & control
  • Mycoplasma Infections / veterinary*
  • Mycoplasma bovis / immunology*
  • Recombinant Proteins / immunology
  • Vaccines, Synthetic / immunology

Substances

  • Adjuvants, Immunologic
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Vaccines
  • Recombinant Proteins
  • Vaccines, Synthetic